{"": [153, 1812, 0], "1. Introduction": [1813, 4658, 0], "2. SARS-CoV-2 Genome Organization": [4659, 7444, 0], "Summary": [15039, 15755, 0, 56854, 57443, 0], "3. SARS-CoV-2 Spike Protein Structure and Functions": [7445, 15755, 1], "4. SARS-CoV-2 Life Cycle": [15756, 19029, 0], "5.1. The Spillover Theory": [19081, 20788, 0], "5.2. Role of Bats": [20789, 24643, 0], "5.3. Possibility of Pangolins as the Intermediate Host ": [24644, 27226, 0], "5.4. Role of S Protein Furin Cleavage Site": [27227, 28724, 0], "5.5. ACE2 Receptor and Intermediate Animal Host Identification": [28725, 33504, 0], "5.6. Role of Other Intermediate Hosts ": [33505, 39611, 0], "5.7. Summary": [39612, 40126, 0], "5. SARS-CoV-2 Transmission from Animals to Humans": [19030, 40126, 1], "6. Diagnostics for SARS-CoV-2 Infection ": [40127, 42418, 0], "7. Food and Drug Administration-Approved Antibody Therapy": [42419, 43624, 0], "8. From SARS-CoV-2 Entry to the Development of Cytokine Storm Syndrome ": [43625, 49299, 0], "9. The Impact of SARS-CoV-2 Variants and Their Role in Viral Infection": [49300, 57443, 1], "10.1. The Impact of Variants on Monoclonal Antibodies and Convalescent Plasma": [57532, 60015, 0], "10.2. The Impact of Variants on Current Vaccinations": [60016, 64538, 0], "10. The Impact of Variants on Monoclonal Antibodies, Convalescent Plasma, and Vaccines": [57444, 64538, 1], "11.1. Antibody-Resistant SARS-CoV-2 Variants": [71912, 74122, 0], "11.2. Summary": [74123, 74852, 0], "11. Vaccine-Associated Adverse Events": [64539, 74852, 1], "12. Concluding Remarks and Future Perspectives": [74853, 76550, 0]}